序贯疗法在幽门螺杆菌根除治疗中的应用进展

发布时间：2018-05-26 09:16

本文选题：幽门螺杆菌 + 序贯疗法　；参考：《山东医药》2017年07期

【摘要】：序贯疗法是一种新型幽门螺杆菌(Hp)根除方法。经典序贯疗法(10 d序贯疗法)前5天应用质子泵抑制剂(PPI)+阿莫西林,后5 d应用PPI+克拉霉素+甲硝唑或替硝唑三联疗法。含铋剂序贯疗法可能会提高Hp根除率。但目前序贯疗法的最佳疗程(10、12、14 d)尚未确定。序贯疗法常用于一线初次治疗的患者。多数序贯疗法疗效优于7 d标准三联治疗方法,少数疗效优于10 d标准三联治疗方法,但与14 d标准三联治疗方法相比无明显差异。序贯疗法总体疗效优于非铋剂四联疗法,但药物不良反应无明显差异;但考虑抗生素成本、患者经济负担,序贯疗法更优于铋剂四联方案。序贯疗法在对克拉霉素和甲硝唑双重耐药的地区需慎重使用,治疗效果不如混合疗法。
[Abstract]:Sequential therapy is a new method for eradication of Helicobacter pylori. Classical Sequential Therapy (10 d Sequential Therapy) was administered with proton pump inhibitor (PPI) amoxicillin 5 days before and PPI clarithromycin metronidazole or tinidazole triple therapy 5 days later. Sequential therapy with bismuth may increase HP eradication rates. However, the optimal course of sequential therapy has not been determined for 10 ~ 12 ~ 14 days. Sequential therapy is often used for first-line treatment of patients. The curative effect of most sequential therapy was better than that of 7-day standard triple therapy, and that of a few was better than that of 10-day standard triple therapy, but there was no significant difference compared with 14-day standard triple therapy. The overall curative effect of sequential therapy was better than that of non-bismuth tetralogy, but there was no significant difference in adverse drug reactions, but considering the cost of antibiotics and the patient's economic burden, sequential therapy was better than bismuth tetralogy. Sequential therapy needs careful use in areas with dual resistance to clarithromycin and metronidazole.
【作者单位】：遵义医学院附属医院;
【基金】：贵州省科技厅社会发展攻关基金资助项目(SY20113056)
【分类号】：R573.1

【相似文献】